In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line

• Published in: Translational oncology Vol. 9; no. 6; pp. 498 - 504
• Main Authors: Zhen, Shuai, Lu, Jiao-Jiao, Wang, Li-Jie, Sun, Xiao-Min, Zhang, Jia-Qi, Li, Xu, Luo, Wen-Juan, Zhao, Le
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2016; Neoplasia Press; Elsevier
• Subjects: Oncology; Original article
• ISSN: 1936-5233; 1936-5233; 1944-7124
• DOI: 10.1016/j.tranon.2016.10.002

Abstract PURPOSE: Human papillomavirus (HPV) type 16 is one of the major etiologic factors of cervical cancer. Our study aims to investigate the potentiality of the antiviral clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system (CRISPR/Cas9) targeting the E6 and E7 oncogenes of HPV16 as a potential chemosensitizer of cisplatin ( cis -diaminedichloroplatinum II; CDDP) for cervical cancer. METHODS : Specifically, the therapeutic efficacy of combination of CDDP and HPV16 E6 + E7-CRISPR/Cas9 was assessed in cervical cancer cells and cervical cancer xenograft models. RESULTS: In vitro experiments showed that long-term exposure of SiHa cells to the HPV16 E6 + E7-CRISPR/Cas9 induced apoptosis, and its pro-apoptosis effect became more obvious when combined with CDDP. In vivo study found the efficacy of the combination of HPV16 E6 + E7-CRISPR/Cas9 and CDDP were superior to either of the treatments in term of apoptosis induction and metastasis inhibition. CONCLUSION: Collectively, our results suggested that HPV16 E6 + E7-CRISPR/Cas9 could be an effective sensitizer of CDDP chemotherapy in cervical cancer.